Yes, buprenorphine is a Schedule III controlled substance under the Controlled Substances Act. The DEA placed buprenorphine and all products containing it into Schedule III in 2002, meaning it has a recognized medical use but also carries some potential for misuse and dependence. This classification sits in the middle of the five-tier scheduling system, below the stricter Schedule I and II categories that include drugs like heroin and oxycodone.
How Buprenorphine Got Its Current Classification
Buprenorphine wasn’t always a Schedule III drug. When it first hit the U.S. market in 1985, it was classified as Schedule V, the lowest level of control. That changed in 2002, when the DEA reviewed updated data and received a recommendation from the Department of Health and Human Services to move it up to Schedule III. The reclassification reflected a better understanding of the drug’s potential for misuse, even though that potential is lower than what you’d see with full-strength opioids like morphine or fentanyl.
Why It’s Controlled but Less Restricted Than Other Opioids
Buprenorphine is a partial opioid agonist, which means it activates the same brain receptors as other opioids but only to a point. Research from Johns Hopkins has confirmed that buprenorphine’s effects hit a plateau at higher doses. Unlike full opioids, where taking more produces stronger effects (including dangerous slowing of breathing), buprenorphine levels off. This ceiling effect is the main reason it’s considered safer and is scheduled lower than drugs like oxycodone or hydromorphone, which are Schedule II.
That said, “safer” doesn’t mean risk-free. Buprenorphine can still produce physical dependence, meaning your body adjusts to its presence and you’ll experience withdrawal symptoms if you stop abruptly. Physical dependence is a predictable biological response, distinct from addiction. With dependence, the brain adapts to the drug but you still maintain control over your decisions and impulses. Addiction, by contrast, involves compulsive drug-seeking, inability to control use, and continued use despite harmful consequences. People who take buprenorphine as prescribed for opioid use disorder are physically dependent on it, but that’s an expected and managed part of treatment.
What Buprenorphine Is Prescribed For
Buprenorphine is FDA-approved for two main purposes: treating opioid use disorder and managing pain. For opioid use disorder, it’s one of three medications the FDA has approved, alongside methadone and naltrexone. It comes in several forms: sublingual tablets or films you dissolve under your tongue, and long-acting injections given under the skin (brands include Sublocade and Brixadi) that release the medication over weeks.
Many buprenorphine products combine it with naloxone, an opioid blocker. You’ll recognize these as Suboxone or Zubsolv. The logic behind the combination is straightforward: when you take the tablet or film under your tongue as directed, the buprenorphine absorbs well (35% to 55% bioavailability) while the naloxone barely absorbs at all (under 10%), so it doesn’t interfere with treatment. But if someone were to crush and inject the product, the naloxone would become fully active and trigger withdrawal symptoms, making misuse unpleasant. Buprenorphine actually binds to opioid receptors about ten times more strongly than naloxone does, so when taken correctly, the naloxone is essentially inert.
How the Schedule III Label Affects You
As a Schedule III substance, buprenorphine comes with specific legal and practical requirements that differ from uncontrolled medications. Pharmacies must keep it in a securely locked cabinet or disperse it among their general stock in a way designed to prevent theft. Any theft or significant loss must be reported to the DEA within one business day. Pharmacies and clinics also cannot employ anyone with a felony drug conviction in a role that involves access to the medication.
For patients, the Schedule III designation means you’ll need a prescription from a provider with a valid DEA registration. Until recently, doctors who wanted to prescribe buprenorphine specifically for opioid use disorder needed a special certification called an X-waiver, which limited how many patients they could treat. That requirement was repealed in early 2023, and the DEA publicly supported the change as a way to expand access. Now, any clinician with a standard DEA license can prescribe buprenorphine for opioid use disorder, removing a significant barrier that had kept many people from getting treatment.
Your prescription can be refilled, unlike Schedule II drugs, which require a new prescription each time. Schedule III medications allow up to five refills within six months of the original prescription date. This makes ongoing treatment more practical, since you won’t need a new office visit every month solely to get a fresh prescription.
How It Compares to Other Controlled Substances
The scheduling system runs from Schedule I (highest restriction, no accepted medical use) through Schedule V (lowest restriction). Here’s where buprenorphine fits relative to drugs people often compare it to:
- Schedule II: Oxycodone, fentanyl, methadone, morphine. These carry high potential for misuse and severe dependence. Prescriptions cannot be refilled.
- Schedule III: Buprenorphine, testosterone, ketamine. Moderate potential for misuse. Prescriptions can be refilled up to five times.
- Schedule IV: Benzodiazepines like alprazolam, sleep medications like zolpidem. Lower misuse potential than Schedule III.
- Schedule V: Certain low-dose cough preparations. Lowest level of control.
Buprenorphine’s placement in Schedule III reflects its ceiling effect and lower overdose risk compared to full opioids, balanced against the reality that it can still be misused and does produce physical dependence. It’s controlled enough to require careful tracking and prescribing oversight, but not so restricted that it creates unnecessary barriers to a medication millions of people rely on for recovery.